Amylase and lipase =< 1.5 x ULN without any symptoms of pancreatitis PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollment PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollment Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored Serum amylase =< 1.5 x ULN Serum lipase =< 1.5 x ULN Patients must have amylase or lipase within =< 1.5 x IULN without symptoms of pancreatitis at registration, within 28 days prior to registration Serum amylase =< 1.5 ULN Serum lipase =< 1.5 ULN Lipase: 1.5 x ULN. Subjects with lipase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis Amylase: 1.5 x ULN. Subjects with amylase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis Serum pancreatic amylase < 1.5 x ULN Serum pancreatic lipase < 1.5 x ULN Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis, within 14 days before the first dose of cabozantinib Serum lipase and amylase =< 1.5 x ULN Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis within 7 days before the first dose of cabozantinib Amylase/lipase =< 1.5 x institutional ULN (without symptoms of pancreatitis) Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis EXCLUSION - INFUSION: Lipase > 70 U/ml Asymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.), at the screening visit Asymptomatic serum amylase =< 2 x ULN; patients with > ULN but =< 2 x ULN serum amylase at study start must be confirmed to have no signs and/or symptoms suggestion pancreatitis or pancreatic injury (e.g. elevated pancreatic [P]-amylase, abnormal imaging findings of pancreas, etc.) Serum lipase =< ULN History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease. Amylase =< 1 x ULN. Lipase =< 1 x ULN. Amylase and lipase =< 2 x ULN Serum amylase =< 1.5 X institutional ULN Lipase =< 1.5 X institutional ULN Obtained within 28 days prior to the first dose of cabozantinib: lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis. Amylase and lipase < 1.5 x ULN obtained ? 14 days prior to randomization Lipase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Amylase and lipase =< 1.5 ULN; subjects with amylase or lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of pancreatitis Serum lipase and amylase =< 1.5 x ULN. Serum lipase > 1.5 x ULN Serum lipase and amylase =< 1.5 x ULN. Lipase =< 1.5 x ULN Serum amylase/lipase =< 1.5 x ULN Serum amylase =< 2 x ULN Serum lipase =< ULN Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase =< 3 x ULN Serum amylase =< ULN Lipase =< ULN FULL STUDY INCLUSION CRITERIA: Amylase and lipase =< 1.5 x ULN Lipase < 2 ULN Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial Serum amylase and lipase =< 2 x ULN Serum amylase and lipase =< 1.5 x ULN Serum amylase and lipase =< 1.5 x institutional ULN Normal serum lipase and amylase (per institutional normal values) Serum amylase =< 2 x ULN Serum lipase =< ULN History of pancreatitis or history of increased amylase or lipase that was due to pancreatitis Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis CAPMATINIB INCLUSION CRITERIA: Serum amylase =< grade 2 and asymptomatic; patients with grade 1 or 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.) CAPMATINIB INCLUSION CRITERIA: Serum lipase =< ULN CERITINIB INCLUSION CRITERIA: Serum lipase =< ULN CERITINIB EXCLUSION CRITERIA: History of pancreatitis, or history of increased amylase or lipase that was due to pancreatic disease Serum amylase =< 2 x ULN Serum lipase =< ULN Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Have normal pancreatic status as defined by the following criterion: a. Serum lipase and amylase ? 1.5 × ULN Amylase =< 2 X ULN For patients being screened for Group 2, asymptomatic serum amylase > CTCAE Grade 2 (1.5-2.0 x ULN). Patients with Grade 1 or Grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.) For patients being screened for Group 2: Serum lipase > ULN Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. Within 4 days prior to the first dose of cabozantinib: Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Serum amylase =< 2 x ULN Serum lipase =< ULN Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Serum lipase and amylase =< 1.5 x ULN Serum lipase =< 2 x ULN Serum amylase =< 2 x ULN Lipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitis Serum amylase =< ULN Serum lipase =< ULN Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Serum lipase and amylase =< 1.5 x ULN Asymptomatic serum amylase grade > 2 (1.5-2.0 x ULN). Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.) Serum lipase > ULN Serum amylase =< ULN Serum lipase =< ULN Within 14 days prior to first dose of study drug treatment: Amylase and lipase =< 1.5 x ULN Within 7 days before the first dose of cabozantinib: Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Amylase < ULN Lipase < ULN Serum amylase and lipase within normal limits Lipase =< 1.5 x the ULN Amylase =< 1.5 x the ULN Within 14 days prior to registration: Serum amylase =< 1.5 x institution’s ULN Within 14 days prior to registration: Serum lipase =< 1.5 x institution’s ULN Amylase and/or lipase =< 1.5 x ULN, obtained =< 7 days prior to registration Lipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitis Lipase > 1.5 ULN; participants with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis Amylase > 1.5 ULN; participants with amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis Lipase < 1.5 times the ULN Fasting serum amylase =< 2 x institutional ULN Fasting serum lipase =< institutional ULN Patients must have a lipase and amylase performed within 7 days prior to sub-study registration Serum amylase and lipase =< 1.5 x the ULN Amylase =< 1.5 x ULN Lipase =< 1.5 x ULN Within 14 days of subject registration: Serum amylase =< 2 x ULN and serum lipase within normal limits Amylase or lipase within normal limit (per institutional standards) Lipase =< 1.5 x upper limit of normal (ULN) Amylase (0-160 U/L) and lipase (0-130 U/L) levels within 1.5 times the range of normal Serum amylase =< ULN Serum lipase =< ULN Amylase and lipase =< 1.5 x the upper limit of normal Patients must have a lipase, amylase, TSH with reflex free T3/T4 performed within 7 days prior to sub-study registration; (Note: For the Canadian sites, testing for lipase only is acceptable) Amylase and lipase <=ULN [Applies to Phase 2]. Lipase < 2 X the upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitis Lipase performed within 28 days of randomization must be less than or equal to 1.5 x ULN for the lab. Lipase =< 1.5 x the ULN Serum amylase =< ULN Serum lipase =< ULN Amylase and lipase ? 2X upper limit of normal Lipase ? 1.5 x ULN Asymptomatic serum amylase or lipase > Grade 2 Serum amylase or serum lipase CTCAE grade ? 1 with signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc) Adequate pancreatic function, defined as amylase and lipase less than or equal to 1.5 X ULN Amylase and lipase =< 2 times institutional ULN for age Obtained =< 7 days prior to registration:\r\nSerum amylase and lipase =< 1.5 x upper limit of normal (ULN) Lipase =< 1.5 x the ULN Lipase less than or equal to 2 x ULN Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease. Serum lipase and amylase =< 2.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 3 x ULN Lipase =< 1.5 x the ULN Serum amylase =< ULN Serum lipase =< ULN Lipase =< 1.5 x the ULN Amylase =< 1.5 x the ULN Serum lipase/amylase ?1.5 x ULN Lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN. Amylase and lipase equal to, or less than, the institutional ULN PART B: Serum lipase =< 1.5 X ULN PART B: Serum amylase =< 1.5 X ULN Normal serum amylase =< (ULN) OR normal Serum lipase =< ULN Obtained =< 7 days prior to registration: Serum lipase =< 1.5 x ULN Serum lipase ? 2 x ULN Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Serum amylase =< 1.5 x ULN Serum lipase =< 1.5 x ULN Have Amylase =< 2.5x ULN Amylase and lipase levels =< ULN Amylase and lipase =< 1.5 x ULN Amylase < 1.5 times ULN Amylase and lipase < 1.5 x of ULN Serum amylase or lipase <1.5 x ULN; Amylase and lipase =< 2 x ULN Amylase and lipase ? 2.5 x ULN (? 5 x ULN for subjects with pancreas involvement with tumor) Lipase levels < 1.5 X ULN Amylase levels < 1.5 X ULN Serum amylase =< ULN Serum lipase =< ULN Amylase =< 1.5 x the ULN Lipase =< 1.5 x the ULN Serum lipase ? 3 x ULN and serum amylase within the normal range Serum lipase ? 3 x ULN and serum amylase within the normal range Lipase and amylase =< 1.5 x ULN Lipase normal limits for the institution Asymptomatic serum amylase > grade 2 Lipase =< 1.5 x ULN Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Serum amylase =< 2 x ULN Serum lipase =< 1 x ULN History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis Serum amylase =< upper limit of normal (ULN) (if > ULN, confirm pancreatic amylase < 1 .1ukat/L and serum lipase < ULN) Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis Serum amylase and lipase within normal limits Amylase =< 1.5 x ULN Lipase =< 1.5 x ULN Amylase and lipase ? 1.5 x ULN History of pancreatitis, or amylase > ULN History of lipase > ULN Serum amylase =< ULN Serum lipase =< ULN Amylase and Lipase < 1.5 x normal for age. Lipase =< 1.5 x the ULN Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis >= grade 2 lipase increased (> 1.5 x ULN) Any history of an immune-related Grade 4 adverse event attributed to prior CIT (other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase) Patients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded. Amylase =< 1.5 x ULN Lipase =< 1.5 x ULN Serum amylase =< 2 x ULN Serum lipase =< ULN Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease Lipase =< 1.5 x the ULN Lipase =< 1.5 ULN Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. Lipase ?1.5×ULN and amylase ?1.5×ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis. At least two episodes of acute pancreatitis in the past 12 months; acute pancreatitis is defined any 2 of the following: (1) typical upper abdominal pain; (2) elevation in serum amylase or lipase >= 3 times upper limit of normal; (3) features of acute pancreatitis on cross-sectional imaging Serum lipase =< 1.5 x ULN Lipase must be <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis and cholecystitis.